CompletedNCT01972711
Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
Medication studyAges 18–45United KingdomSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- Headington and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateMarch 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 105
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT01972711
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Headington · Manchester
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SEP-363856, Amisulpride and Placebo.
Who was this study for?
Listed age limits: 18 years to 45 years.
